医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NEWS > Home > > 疾病 > AIDS >

Australian Olympic Team Taking Dual Protect™ VivaGel® Condoms to Rio

2016年05月16日 PM01:32
このエントリーをはてなブックマークに追加


 

MELBOURNE, Australia

Starpharma Holdings Ltd (ASX:SPL) (OTCQX:SPHRY) and Ansell Limited (ASX:ANN) today proudly announce that the Australian Olympic team will be provided with antiviral Dual Protect™ VivaGel® condoms for the upcoming Olympic Games in Rio de Janeiro.

Dual Protect™ is the world’s only antiviral condom, which is currently marketed by Ansell in Australia. While the physical barrier of the condom provides primary protection, the condom lubricant contains VivaGel®, an antiviral agent that has been proven in laboratory studies to inactivate HIV, HSV (genital herpes) and HPV (human papillomavirus), which are viruses that cause sexually transmitted infections (STIs).

Starpharma has also recently announced that the antiviral active, VivaGel®, showed near-complete antiviral protection against Zika virus in laboratory studies at levels significantly below the concentration in the Dual Protect™ condom. It is now known that Zika virus can be sexually transmitted.

VivaGel® is an Australian innovation developed by Starpharma, who has teamed up with Ansell to create the Dual Protect™ condom. This world-first innovation, also developed and first available in Australia, is currently in the process of being rolled-out to other countries around the world.

“Starpharma is delighted to play a role in supporting Australian athletes as they compete on the world-stage at the Olympic Games in Rio,” said Starpharma Chief Executive Officer, Dr Jackie Fairley. “Given sexual transmission of Zika virus is of increasing importance the potent activity of Starpharma’s VivaGel® against Zika could prove very significant.”

“As a global leader in protection solutions, Ansell is proud to support the Australian Olympic team during the Olympic Games in Brazil,” said Jeyan Heper, President and General Manager, Sexual Wellness Global Business Unit at Ansell.

“Ansell’s mission is to provide innovative solutions for safety, well-being and peace of mind, no matter who or where you are, and our LifeStyles® Dual Protect™ condoms, developed in cooperation with Starpharma, combines a high-quality condom with patented anti-viral technology.”

The Chef de Mission of the 2016 Australian Olympic Team, Kitty Chiller said “the health and wellbeing of the Team comes first and our association with Starpharma will provide extra protection for everyone on the Team, and is a common sense approach to a very serious problem we are facing in Rio”.

For more information on Dual Protect™ VivaGel® condoms, see: http://www.ansellcondoms.com.au/products/lifestyles-dual-protect-condoms

For more information on VivaGel®, see: http://www.starpharma.com/the_vivagel_condom

View source version on businesswire.com: http://www.businesswire.com/news/home/20160515005051/en/

CONTACT

Media:
Buchan Consulting
Rebecca Wilson, +61 417
382 391
rwilson@buchanwe.com.au
Arthur
Chan, +61 2 9237 2805
achan@buchanwe.com.au
or
Starpharma:
Dr
Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and
Company Secretary
+61 3 8532 2704
ruth.dimmack@starpharma.com
investor.relations@starpharma.com
or
Ansell:
Tom
Paolella, +1 732 345-2167
Global Communications
tom.paolella@ansell.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究